MedTrace Logo

Clinical Trial of Vildagliptin in Early Parkinson's Disease

NCT06951334 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2025-04-30

No results posted yet for this study

Summary

Investigating the efficacy of Vildagliptin in delaying the progression of Parkinson's disease.

Conditions

  • Parkinson's Disease

Interventions

DRUG

Vildagliptin 50 mg bid

Vildagliptin 50 mg bid for 12months

Sponsors & Collaborators

  • First Affiliated Hospital, Sun Yat-Sen University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-01
Primary Completion
2026-12-31
Completion
2026-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06951334 on ClinicalTrials.gov